Bray G P, Williams R
Institute of Liver Studies, King's College Hospital School of Medicine and Dentistry, Denmark Hill, London, UK.
J Autoimmun. 1992 Apr;5 Suppl A:293-300. doi: 10.1016/0896-8411(92)90047-t.
Since autoimmune processes are probably involved in the early stages of primary biliary cirrhosis (PBC), immunomodulatory drugs have been investigated with the aim of prolonging survival, delaying transplantation, slowing histological progression and relieving symptoms. Corticosteroids, azathioprine, chlorambucil and, more recently, cyclosporin A and methotrexate have all be subjected to clinical investigation. In the latest of these, a European multicentre trial, cyclosporin A has been shown to delay death or transplantation with a reduction in liver related deaths and slowing of the rise of serum bilirubin. The incidence of nephrotoxicity and hypertension are low at the doses used.
由于自身免疫过程可能参与原发性胆汁性肝硬化(PBC)的早期阶段,人们已对免疫调节药物进行了研究,目的是延长生存期、推迟移植、减缓组织学进展并缓解症状。皮质类固醇、硫唑嘌呤、苯丁酸氮芥,以及最近的环孢素A和甲氨蝶呤都已接受临床研究。在这些研究中的最新一项,即一项欧洲多中心试验中,已表明环孢素A可延缓死亡或移植,同时降低肝脏相关死亡,并减缓血清胆红素的升高。在所使用的剂量下,肾毒性和高血压的发生率较低。